Celladon Corporation Completes Enrollment Of CUPID 2 Trial For Advanced Heart Failure
3/4/2014 9:01:47 AM
SAN DIEGO, March 4, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced it has completed enrollment and randomized 250 patients in the phase 2b trial titled "Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease," known as CUPID 2, which is evaluating the efficacy and safety of MYDICAR (AAV1/SERCA2a) in patients with NYHA class III/IV symptoms of systolic heart failure.
Help employers find you! Check out all the jobs and post your resume.
comments powered by